CAJ | 학술논문

目的：评估阿立哌唑治疗首发精神分裂症的临床疗效和安全性。方法将80例首发精神分裂症患者随机分为阿立哌唑组和利培酮组（各40例），治疗前后分别评定阳性及阴性症状量表（PANSS），以PANSS减分率评定疗效，副反应量表（ TESS）及实验室相关检查评定药物副反应。结果治疗8周后，两组PANSS各项评分较治疗前均显著降低（ P＜0.05），两组PANSS各项评分减分比较差异均无统计学意义（ P＞0.05）；阿立哌唑组总有效率为72.5％，对照组总有效率为70.0％，两组总有效率比较差异无统计学意义（ P＞0.05）；两组均未发生严重相关不良事件。结论阿立哌唑是一种安全有效的抗精神病药物，对首发精神分裂症的疗效与利培酮相当。
목적：평고아립고서치료수발정신분렬증적림상료효화안전성。방법장80례수발정신분렬증환자수궤분위아립고서조화리배동조（각40례），치료전후분별평정양성급음성증상량표（PANSS），이PANSS감분솔평정료효，부반응량표（ TESS）급실험실상관검사평정약물부반응。결과치료8주후，량조PANSS각항평분교치료전균현저강저（ P＜0.05），량조PANSS각항평분감분비교차이균무통계학의의（ P＞0.05）；아립고서조총유효솔위72.5％，대조조총유효솔위70.0％，량조총유효솔비교차이무통계학의의（ P＞0.05）；량조균미발생엄중상관불량사건。결론아립고서시일충안전유효적항정신병약물，대수발정신분렬증적료효여리배동상당。
Objective To assess the efficacy and safety of aripiprazole in the treatment of first-episode schiz-ophrenia.Methods Eighty patients with first-episode schizophrenia were randomized into aripiprazole group (n=40) and risperidone group(n=40).The positive and negative syndrome scale (PANSS) and treatment emergent symptom scale(TESS) were used to assess the effectiveness and the safety of the treatment .Results The scores of PANSS de-creased significantly comparing to the base line in both groups ( P<0.05 ) and without statistically difference between two groups(P>0.05) by the end of the 8 weeks treatment;There is no marked difference between two groups in the decrease of all elements of PANSS after 8-week treatment ( P>0.05 );The total efficacious rate of aripiprazole group was 72.5%and that of risperidone group was 70.0%, the secondary reaction of two groups was less .Conclusion Aripiprazole is a safe and effective antipsychotics ,it has similar efficacy to risperidon in the antipsychotic treatment .